pentobarbital will minimize the level or effect of hydrocortisone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.
pentobarbital will minimize the extent or impact of naloxegol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Usage of naloxegol with robust CYP3A4 inducers isn't advisable
pentobarbital will decrease the level or influence of sulfamethoxazole by impacting hepatic enzyme CYP2C9/10 metabolism. Minor/Importance Not known.
pentobarbital will lessen the extent or outcome of armodafinil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unknown.
pentobarbital will lessen the level or effect of donepezil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Mysterious.
Make sure you Take note which the site you may have asked for is just not offered as part of your default language. You will be applying our System in Yet another language now.
Contraindicated. Coadministration of doravirine with a robust CYP3A inducer may well lower doravirine plasma concentrations and/or consequences. Probable for lack of virologic response and feasible resistance to doravirine.
pentobarbital will lower the extent or effect of ziprasidone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unfamiliar.
pentobarbital will reduce the extent or influence of diltiazem by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
benzhydrocodone/acetaminophen check here and pentobarbital equally raise sedation. Prevent or Use Alternate Drug. Limit use to individuals for whom option therapy alternatives are inadequate
pentobarbital improves consequences of ifosfamide by influencing hepatic enzyme CYP2B6 metabolism. Use Caution/Watch. Coadministration of ifosfamide with CYP2B6 inducers may perhaps raise metabolism of ifosfamide to its metabolite. Keep track of for increased outcomes/toxicities if combined with CYP2B6 inducers.
Contraindicated (one)pentobarbital will lessen the level or influence of lumacaftor/ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
buprenorphine, extended-performing injection and pentobarbital each increase sedation. Keep away from or Use Alternate Drug. Restrict use to sufferers for whom substitute therapy solutions are insufficient
pentobarbital will lessen the level or influence of atogepant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Recommended atogepant dosage with concomitant usage of strong or average CYP3A4 inducers is 30 mg or sixty mg qDay.